Header | ||
---|---|---|
Header | Header | Header |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Adapted from Corey G, et al. 2010.
*There is no experience with ZINFORO® in the treatment of cSSTI in the following patient groups4: The immunocompromised, patients with severe sepsis/septic shock, necrotising fasciitis, perirectal abscess and patients with third-degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.
CANVAS, CeftAroliNe fosamil versus VAncomycin in Skin and skin structure infection; CI, confidence interval; cSSTI, complicated skin and soft tissue infection; q12h, every 12 hours.
References:
Safety profile consistent with other cephalosporins
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.